TWi Biotechnology, Inc


Chairman: Dr. Chih-Ming Chen
Established: 2010/07/16  
Tel: 886-2-2657-3350 
Fax: 886-2-2657-0270 
Address: 3F, No.41, Lane 221, Kang Chien Road, Nei Hu Dist., Taipei 114, Taiwan
                                 Website: http://www.twibiotech.com/


 

Company Profile:

TWi Biotechnology, Inc. (TWi) was founded in 2010, Taiwan. The Corporate Philosophy is using innovation, quality, and efficiency as its core competency to focus on the new drug research and development, toward becoming a world-class and a specialty pharmaceutical company. For enhancing the company's value, we increase the visibility of Taiwan in drug development, and raise the position in the world's drug research, in order to build an international business vision of biotechnology industry in Taiwan.

TWi’s R&D strategy is divided into two general directions; one is researching and developing new drugs by our own, focusing on drug reposition with new indication and/ or new formulation of old drugs. The other is licensing in potential projects, coupled with company's experience of new drug development, preclinical and clinical development and construct related patent of protections.

After moving new drug development into clinical phase I to II, TWi will actively look for big pharmaceutical companies to take over the subsequent development and the market.Strategy of TWi is able to increase the flexibility and success of new drug development, and enables TWi to connect the trend of the global new drug development.

New Drug in Development:

 

Project Name

Indication

Mechanism

Stage

AC-201

Type II diabetes mellitus & Gout

IL-1ß modulator

Both Type II diabetes mellitus & Gout indications are in Phase II development stage.

AC-701

Immune-related dermal disease

Anti-inflammatory modulator

The phase II clinical trial is ongoing in Taiwan.